Baker Idi Heart and Diabetes Institute Holdings Limited

Affimed Therapeutics, Ag

Emory University

Csl Limited

Albert-ludwigs-universitat Freiburg

Universitaetsklinikum Freiburg

Universitätsklinikum Freiburg

Starpharma Pty Limited

Karlheinz Peter

Andreas Zirlik

Dennis Wolf

Melvyn Little

Stefan Knackmuss

Peter Roettgen

Meike Schwarz

Yung-Chih Chen

Elliot L Chaikof

Con Panousis

Guy Yeoman Krippner

David James Owen

Zemin Wu

Carolyn A Haller

Claudia Linhard

Hamid Hosseini

Claudia Buettner

Christoph Hagemeyer

Danijal Topcic

Nay Min Htun

Wookhyun Kim

The present disclosure relates to a method of treating or preventing atherosclerosis in a subject by administering an inhibitor of FXII.

Method of treating atherosclerosis

The CD40L/Mac-1 interaction is selectively targeted by small peptide inhibitors and/or antibodies and such peptides are used for the specific treatment of inflammation and atherogenesis. In particular, pharmaceutical compositions comprising a polypeptide having the amino acid sequence EQLKKSKTL and antibodies specifically binding to an epitope are disclosed.

Selective targeting of the CD40L/Mac-1 interaction by small peptide inhibitors and its use for the treatment of inflammation and atherogenesis

The present invention provides an isolated monoclonal antibody or an antigen-binding portion thereof which a) binds to Mac-1, b) specifically inhibits the interaction of CD40L with activated Mac-1 and c) does not induce integrin outside-in signaling.

Antibodies against Mac-1

An apparatus detects atherosclerotic plaques. The apparatus includes an electronic processing device that determines a level of fluorescence sensed by a sensor at a second infrared wavelength in response to exposure of at least part of an artery to radiation at a first infrared wavelength and determines a fluorescence indicator using the level of fluorescence. The fluorescence indicator is indicative of the presence, absence or degree of an atherosclerotic plaque.

Atherosclerotic plaque detection

The present invention provides an anticoagulant agent including a first element capable of inhibiting coagulation and a second element capable of targeting an activated platelet wherein upon administration of the agent to a subject the second element directs the first element to the activated platelet. Also provided is a probe for detecting a blood vessel abnormality including (a) a binding element capable of targeting an activated platelet and (b) a label. Applicant has shown that agents and probes directed to activated platelets are useful in the diagnosis and therapy of coagulation disorders.

Single chain antibodies that specifically bind to the activated state of the platelet integrin receptor GP IIb/IIIa

The present invention relates generally to branched macromolecules and their use as imaging or contrast agents. In particular, the invention relates to dendrimers, derived from lysine or lysine analogs, bearing a plurality of functional moieties and their application to imaging techniques in which a disease state may be imaged with a targeted contrast agent.

Polylysine dendrimer contrast agent

This disclosure relates to temperature sensitive conjugates, compositions, and uses related thereto. In certain embodiments, the disclosure relates to conjugate polymers comprising a) a temperature sensitive polymer and b) an antibody. Typically the antibody has an epitope to a platelet receptor. The antibody may be a single-chain antibody wherein the platelet receptor is GPIIb/IIIa, such as an anti-GPIIb/IIIa antibody. In certain embodiments, the antibody binds specifically to the activated conformation of GPIIb/IIIa, i.e., an activation-specific GPIIb/IIIa antibody.

Temperature sensitive conjugate compositions

The present invention is directed to an antibody or derivative thereof of human origin for inhibiting platelet aggregation, characterized in that it is effective by substantially exclusive binding to the activated state of platelet integrin receptor GPIIb/IIIa.

Human antibody specific for activated state of platelet integrin receptor GPIIb/IIIa

Antibody of human origin specifically binding to activated state of platelet integrin receptor GPIIb/IIIa

Growing community of inventors

Hawthorn East, Australia

Karlheinz Peter